Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Oppenheimer started coverage of Dianthus Therapeutics (NASDAQ:DNTH) with an outperform rating, citing the market potential of ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Dianthus Therapeutics, a clinical-stage biotechnology company, has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology industry ...